Subscribe To
Roche settles us patent lawsuit against biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over i...
October 23, 2023, 3:28 pm
Roivant sciences sells joint venture with pfizer to roche for $7.1 billion
London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is c...
October 23, 2023, 3:25 pm
Hsbc says buy marriott now
The "Halftime Report" traders debate the biggest analyst calls of the day....
October 23, 2023, 1:37 pm
It doesn't seem like there's too much momentum for healthcare stocks, says mizuho's jared holz
Jared Holz, Mizuho healthcare sector specialist, joins 'Squawk on the Street' to discuss how Holz broadly sees the b...
October 23, 2023, 12:07 pm
Astrazeneca boss pascal soriot dismisses exit talk
AstraZeneca PLC (LSE:AZN) boss Pascal Soriot has told Bloomberg that reports of his imminent departure ...
October 23, 2023, 10:01 am
Mara vs riot: the ultimate winner for best returns if you invested $1,000 in these two stocks when bitcoin was under $17,000
The value of Bitcoin (CRYPTO: BTC) surged to levels around $30,000, largely attributed to the renewed optimism for Securities and Exchange Commission ...
October 23, 2023, 8:29 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceuti...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceuti...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceuti...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceuti...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceuti...
October 23, 2023, 5:00 am
7 biotech stocks to get in now before investors catch on
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us...
October 23, 2023, 2:50 am
Stock market etfs to watch: semiconductors (smh), biotechnology (ibb), regional banks (kre)
Most of you know our Big View product, since I often talk about our risk gauges. In fact, I can report to you that our risk gauges show 3 out of the...
October 22, 2023, 1:29 pm
United therapeutics: both fundamental and technical analyses justify a buy decision
United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a com...
October 22, 2023, 12:25 pm
Is it time to buy the s&p 500's 3 worst-performing stocks this year?
Amid dimming immediate prospects, the solar sector's long-term resilience could light the way for patient investors. Moderna's post-pandemic journey u...
October 22, 2023, 10:13 am
Iovance biotherapeutics: testing shareholders' patience
Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment o...
October 22, 2023, 9:12 am
Elliott wave analysis of eurusd – october 23rd, 2023
In today's Elliott Wave analysis of EURUSD we examine the pair's weekly, daily and 4h charts. A trading...
October 22, 2023, 7:25 am
Elliott wave analysis of usdjpy – october 23rd, 2023
USDJPY missed the 150.00 mark by less than a pip last week as rising treasury yields pushed the greenback up against the Japanese yen. Can the pair so...
October 21, 2023, 11:33 am
Elliott wave analysis of usdcad – october 23rd, 2023
USDCAD closed above 1.3700 for the first time since March on the back of rising US treasury yields and hesitant crude oil bulls. How far is this uptre...
October 21, 2023, 9:54 am
Beam therapeutics stock: bear vs. bull
Pre-revenue biotechs like Beam Therapeutics bring plenty of risk. The good news is that it has plenty o...
October 21, 2023, 8:45 am